[HTML][HTML] A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide+/-RRx-001 in newly …
H Fine, T Reid, S Caroen, B Oronsky, N Abrouk… - Frontiers in …, 2023 - frontiersin.org
Introduction The current standard of care for newly diagnosed glioblastoma (GBM) is
maximum surgical resection followed by concurrent treatment with temozolomide (TMZ) and …
maximum surgical resection followed by concurrent treatment with temozolomide (TMZ) and …
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide+/-RRx-001 in newly diagnosed …
H Fine, T Reid, S Caroen, B Oronsky… - Frontiers in …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction The current standard of care for newly diagnosed glioblastoma (GBM) is
maximum surgical resection followed by concurrent treatment with temozolomide (TMZ) and …
maximum surgical resection followed by concurrent treatment with temozolomide (TMZ) and …
A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide+/-RRx-001 in newly diagnosed …
H Fine, T Reid, S Caroen, B Oronsky, N Abrouk… - Frontiers in …, 2023 - europepmc.org
Methods In this non-randomized, open-label, two part trial called G-FORCE-1
(NCT02871843), the first four cohorts of adult patients with histologically confirmed high …
(NCT02871843), the first four cohorts of adult patients with histologically confirmed high …
[HTML][HTML] A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide+/-RRx-001 in newly …
H Fine, T Reid, S Caroen, B Oronsky… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Results A total of 16 newly diagnosed glioblastoma patients were enrolled. No dose limiting
toxicities were observed and no MTD was reached. The recommended dose is 4 mg. After …
toxicities were observed and no MTD was reached. The recommended dose is 4 mg. After …